The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

Earlier studies indicated that COVID infection might cause MS symptoms to worsen, particularly if the symptoms coincide with those associated with long COVID. For this new study, researchers tracked ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...

is the most common type of multiple sclerosis (MS), making up about 85% of diagnoses. RRMS involves periods known as relapses, during which symptoms worsen, followed by periods of symptom ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

Since announcing her multiple sclerosis diagnosis in 2018, Selma Blair has been an outspoken advocate for people with MS. The ...

Speaking about the incident, the mum said: “I was met with the most abusive woman who ridiculed me and my disability. “I ...